Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
Standard
Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years. / Daghia, Giulia; Zabelina, Tatjana; Zeck, Gaby; von Pein, Ute-Marie; Christopeit, Maximilian; Wolschke, Christine; Ayuk, Francis; Kröger, Nicolaus.
in: EUR J HAEMATOL, Jahrgang 103, Nr. 4, 10.2019, S. 370-378.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
AU - Daghia, Giulia
AU - Zabelina, Tatjana
AU - Zeck, Gaby
AU - von Pein, Ute-Marie
AU - Christopeit, Maximilian
AU - Wolschke, Christine
AU - Ayuk, Francis
AU - Kröger, Nicolaus
N1 - © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2019/10
Y1 - 2019/10
N2 - INTRODUCTION: Myelofibrosis (MF) is a disease of elderly with median age of 65 years at diagnosis. Allogeneic stem cell transplantation (ASCT) currently is the only potentially curative option, although associated with treatment-related morbidity and mortality. Development of reduced intensity conditioning (RIC) regimens enabled transplant to be performed successfully in older patients.OBJECTIVES AND METHODS: To evaluate outcome of transplantation among elderly patients (≥65 years), we conducted retrospective analysis of results in 45 patients transplanted between 2002 and 2018 at the University Medical Center Hamburg. Median age at ASCT was 67 years (r: 65-74). The majority of patients (n = 43) received busulfan plus fludarabine RIC regimen and were classified as DIPSS intermediate-2 or high risk at time of transplantation.RESULTS: After a median follow-up of 4 years, 6-year estimated progression-free survival and overall survival were 60% and 64%, respectively. Cumulative incidence of non-relapse mortality was 21% at 1 year. Cumulative incidence of relapse at 6 years was 10%. Patients with Sorror score 3 or less had a significant better survival (73% vs 25%, P = .009).CONCLUSION: Reduced intensity conditioning regimen followed by ASCT in older patients with myelofibrosis is a curative treatment option. Outcome is more favorable in patients with no or minimal comorbidities.
AB - INTRODUCTION: Myelofibrosis (MF) is a disease of elderly with median age of 65 years at diagnosis. Allogeneic stem cell transplantation (ASCT) currently is the only potentially curative option, although associated with treatment-related morbidity and mortality. Development of reduced intensity conditioning (RIC) regimens enabled transplant to be performed successfully in older patients.OBJECTIVES AND METHODS: To evaluate outcome of transplantation among elderly patients (≥65 years), we conducted retrospective analysis of results in 45 patients transplanted between 2002 and 2018 at the University Medical Center Hamburg. Median age at ASCT was 67 years (r: 65-74). The majority of patients (n = 43) received busulfan plus fludarabine RIC regimen and were classified as DIPSS intermediate-2 or high risk at time of transplantation.RESULTS: After a median follow-up of 4 years, 6-year estimated progression-free survival and overall survival were 60% and 64%, respectively. Cumulative incidence of non-relapse mortality was 21% at 1 year. Cumulative incidence of relapse at 6 years was 10%. Patients with Sorror score 3 or less had a significant better survival (73% vs 25%, P = .009).CONCLUSION: Reduced intensity conditioning regimen followed by ASCT in older patients with myelofibrosis is a curative treatment option. Outcome is more favorable in patients with no or minimal comorbidities.
U2 - 10.1111/ejh.13294
DO - 10.1111/ejh.13294
M3 - SCORING: Journal article
C2 - 31306511
VL - 103
SP - 370
EP - 378
JO - EUR J HAEMATOL
JF - EUR J HAEMATOL
SN - 0902-4441
IS - 4
ER -
